Curis, Inc. ("Curis") , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback